

# Bomi Italia S.p.A.

– PRESS RELEASE –

## A total of Euro 3.5 million received in commitments to subscribe to the share capital increase.

**Vaprio d'Adda, 5 April 2018** – Bomi Italia S.p.A. ("**Bomi**" or the "**Company**" or the "**Issuer**"), Parent Company of the Bomi Group, a world leader in the biomedical logistics sector and in the management of high technology healthcare products, which is listed on the multilateral trading platform of **AIM Italia / Alternative Capital Market**, regulated and managed by Borsa Italiana S.p.A., following the press release of 29 March 2018, communicated that it has received binding commitments from shareholders with rights to subscribe to the **share capital increase of Euro 4.99 million** to be proposed at the next Shareholders' Meeting.

Commitments to subscribe to their rights have come from some of the "significant" shareholders: **Quaestio Capital Management SGR S.p.A.** (on behalf of Quaestio Italian Growth Fund) for Euro 3.0 million and **First Capital S.p.A.** for Euro 0.5 million at a maximum issue price of Euro 3.0 per share.

Furthermore, Mr Giorgio Ruini, Mr Marco Ruini, Ms Silvia Ruini and the companies Incab & Co S.r.l., Palmberg International B.V. (the majority shareholder in the Company) and Exential Consulting S.r.l. have agreed to sell all their **rights** in the aforementioned share capital increase to Quaestio Capital Management SGR S.p.A. (on behalf of Quaestio Italian Growth Fund) for a payment of Euro 0.032 for each right.

This will permit to Quaestio Capital Management SGR S.p.A. (on behalf of the Quaestio Italian Growth Fund) to strengthen its position as the second largest shareholder in the Company and as strategic partner of the Ruini family, becoming a "significant" shareholder in the Company.

BPER Banca S.p.A. has underwritten the remaining part of the aforementioned share capital increase thereby guaranteeing its success.

---

**Bomi Italia S.p.A.** is the Parent Company of Bomi Group, a world leader in the biomedical logistics sector and in the management of high technology healthcare products. It was one of the first companies to receive the "Elite" certificate issued by Borsa Italiana.

Bomi Group's activities are concentrated in the integrated logistics sector and offer a wide range of logistics services in outsourcing to companies operating in the healthcare sector, managing distribution of medical equipment, pharmaceuticals, in-vitro diagnostic equipment, reagents and implant products.

Bomi Group's portfolio of about 100 clients includes some of the world's top healthcare companies (such as the leading pharmaceutical companies and producers of healthcare devices) as well as small and medium sized companies operating at a global level in the biomedical, diagnostics and biotech industries.



*Bomi Group currently has about 1,080 employees and operates through subsidiary companies and associated companies in Europe, South America, China and the United States and its services are also provided, through strategic alliances with local partners.*

*ISIN Ordinary Share Code: IT0005108748 – Ordinary Share Ticker: BOMI*

*ISIN Convertible Bond Code: IT0005114480 – Convertible Bond Ticker: BOMI20*

**Bomi Italia S.p.A. •**

Investor Relator  
tel: +3903962781313  
e.mail: investorrelator@bomigroup.com

**IR Top**

IR & Financial Communication  
Tel. +39 45473883  
Email: @ir@irtop.com

**BPER Banca S.p.A. •**

Nominated Adviser  
tel: +390512756537  
e.mail: bomi@bper.it

